The first one, the EMPA-REG OUTCOME trial, investigated in 7020 T2DM patients with overt cardiovascular disease the effect of empagliflozin on a primary combined endpoint of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke [1]
Contact Dermatitis 35(3):175176 Mayorga C, Celik G, Rouzaire P, Whitaker P, Bonadonna P, Rodrigues-Cernadas J, Vultaggio A, Brockow K, Caubet JC, Makowska J et al (2016) In vitro tests for drug hypersensitivity reactions: an ENDA/EAACI Drug Allergy Interest Group position paper
Nitric Oxide Synthesis and Function Vasodilators, such as acetylcholine, bradykinin, and adenosine do not exert their effects upon the vascular smooth muscle cells in the absence of the overlying endothelium
BMC Genomics 21:145
What should patients know about the mental health effects of GLP-1 receptor agonists